

## Application News

Liquid Chromatograph Mass Spectrometer LCMS-8060NX

# Simultaneous Quantitation of N-nitrosamines and NDSRI in API and Formulation by Using a DUIS™ Ionization Source in LC-MS/MS

Nitish Suryawanshi, Shalu Nair, Samruddha Chavan, Nitin Shukla, Devika Tupe, Siddhesh Ghadi, Ramesh Manigiri, Jitendra Kelkar, Pratap Rasam  
Shimadzu Analytical (India) Pvt. Ltd.

### User Benefits

- ◆ Single method for simultaneous detection of both N-nitrosamines and NDSRI by using LC-MS/MS.
- ◆ A novel LC-MS/MS ionization source enabling selective and sensitive detection of both N-nitrosamines and NDSRI.
- ◆ Simple and sensitive LC-MS/MS method to quantify nine N-nitrosamines impurities and 1 NDSRI without any complex sample pre-treatment.

### Introduction

N-nitrosamines have been monitored extensively in pharmaceuticals since 2018. Since 2020, there has been an increased number of reports of more structurally complex N-nitrosamines related to the structure of the active substance itself in several drug products. These are often referred to as “nitrosamine drug substance related impurities” (NDSRIs) and are generally formed by nitrosation of an amine moiety present in the active substance. After N-nitrosamines, the US Food and Drug Administration (FDA) now demands the pharmaceutical manufacturers to establish if their active pharmaceutical substance (API) or formulation is free from NDSRIs. Considering the risk associated and regulatory implications, there is an increasing demand for testing of both these type of molecules in API and formulations. N-nitrosamines are typically monitored using atmospheric pressure chemical ionization (APCI) in LCMS analysis. This preference is due to their smaller molecular size, which can result in higher background interference when using electrospray ionization (ESI). In contrast, NDSRIs are primarily analyzed using ESI because they exhibit higher sensitivity with this ionization method. Considering the above scenario, API and formulations with potential of having presence of both N-nitrosamines and NDSRIs need to be tested with multiple methods. Consumption of chemicals, reagents and decreasing throughput are some of the drawbacks associating with such multiple testing. This leads to a high demand for having a method with simultaneous detection of both N-nitrosamines and NDSRI using LC-MS/MS. For simultaneous detection, a dual ionization source (DUIS) can be very useful as it can ionize both the N-nitrosamines and NDSRIs using same interface. Optimum sensitivities for individual compounds can be achieved by optimizing the source conditions to either have ESI like or APCI like conditions. This application news describes a partially-validated LC-MS/MS procedure for quantitation of nine N-nitrosamines and NDSRI in Afatinib API and formulation which was performed using an Ultra High Performance Liquid Chromatograph (UHPLC) Nexera™ X3 coupled with LCMS-8060NX, a Triple Quadrupole Mass Spectrometer equipped with a DUIS source from Shimadzu Corporation, Japan (Figure 1).

The nine N-nitrosamines and one NDSRI includes N-nitroso-dimethylamine (NDMA), N-nitrosomethylethylamine (NMEA), N-Nitrosopyrrolidine (NPYR), N-nitroso-diethylamine (NDEA), N-nitrosopiperidine (NPIP), N-nitroso-ethyl-isopropylamine (NEIPA), N-nitroso-diisopropylamine (NDIPA), N-nitroso-dipropylamine (NDPA), N-nitroso-dibutylamine (NDBA) and N-nitroso Afatinib impurity-2 (N-AFA).

### Method Development

Individual standards for all nine N-nitrosamines and NDSRI were purchased locally. Stock solutions for individual N-nitrosamines and NDSRI were prepared and analysed in scan mode. Further, steps such as precursor ion selection, Multiple Reaction Monitoring (MRM) optimization at different

Collision Energies (CE) and voltage optimization were performed using Shimadzu's LabSolutions™ auto MRM optimization feature to obtain MRMs and their optimum CEs. To achieve optimum sensitivity, parameters such as interface voltage and focus voltage were fine tuned. An LC method (Table 1) was developed with an aim to separate 10 compounds and API under study which was achieved using Shimadzu make Shim-pack Scepter™ PFPP (Metal free), 2.1 mm I.D. x 100 mm and 3.0 µm LC column (P/N: 227-31089-02).

Optimized MRMs for individual compounds are listed in Table 2. For quantitation, a linearity ranging from 1.0-20.0 ppb for NDMA, 0.5-20.0 ppb for NMEA, NPYR, NPIP, NDEA, NEIPA, NDIPA, NDPA, NDBA and 0.5-7.5 ppb for N-AFA was prepared in diluent and was analyzed using LC-MS/MS. The limit of quantitation (LOQ) was found to be 1.0 ppb for NDMA and 0.5 ppb for rest of the compounds. The S/N and % RSD at LOQ are shown in Table 3.



Figure 1: Shimadzu Nexera™ X3 UHPLC coupled with an LCMS-8060NX Triple quadrupole mass spectrometer

### Method

Table 1. Instrument parameters for LC-MS/MS

HPLC System	: Nexera X3
Column	: Shim-pack Scepter PFPP-120 (Metal free) 2.1 mm I.D. x 100 mm, 3 µm (P/N:227-31089-02)
Column Temp.	: 45 °C
Mobile Phases	: A:10 mM ammonium formate in water B: Methanol:Acetonitrile (9:1) v/v
Flow Rate	: 0.45 mL/min
Gradient Program (B%)	: B Conc. 2 % (0-3 min)→40 % (8 min)→70 % (20 min)→100 % (21-25 min)→ 2 % (25.5-35 min)
Injection Volume	: 40 µL
MS	: LCMS-8060NX
Ionization Source	: DUIS™
Temperature	: Interface: 400°C Desolvation Line: 250°C Heater Block: 400°C
Gas Flows	: Nebulizing Gas: 3.0 L/min Drying Gas: 4.0 L/min

Table 2: MRM transitions for 9 N-nitrosamines and 1 NDSRI

Compound	Precursor m/z	Product m/z	CE
NDMA	74.90	58.05	-10
NMEA	89.20	61.25	-15
NPYR	101.00	55.25	-18
NDEA	103.00	29.05	-16
NPIP	115.05	41.00	-22
NEIPA	117.00	75.10	-13
NDIPA	131.10	89.15	-12
NDPA	131.00	89.05	-12
NDBA	159.00	41.05	-22
N-AFA	501.05	414.00	-23

## Sample preparation:

Figure 2 depicts the sample preparation protocol for API and formulation samples and spiked samples.




Figure 2: Sample and spiked sample preparation

## Results and discussion:

Figure 3.1 and 3.2 depict the chromatographic peak separation between Afatinib API detected in UV and Nitrosamines and N-AFA detected in MRM mode.

Figure 4 depicts the calibration curve and LOQ level standard (Representative chromatograms of 3 compounds).




Figure 4: a, c, e depict chromatograms for LOQ level solution for 3 representative compounds  
b, d, f depict calibration curve for 3 representative compounds




Figure 3.1: UV chromatogram of Afatinib API spiked sample




Figure 3.2: MS chromatogram of Afatinib API spiked sample

Table 3: Coefficient of determination for calibration curves, repeatability of area for LOQ solution and S/N ratio for LOQ solution (Conc. expressed are as such)

Abbr.	r <sup>2</sup>	CC Range (ppb)	LOQ		
			Conc. (ppb)	% RSD (n=6)	S/N
NDMA	0.993	1.0-20.0	1.0	11.0	30
NMEA	0.999	0.5-20.0	0.5	8.2	52
NPYR	0.998	0.5-20.0	0.5	12.3	66
NDEA	0.999	0.5-20.0	0.5	11.0	89
NPIP	0.999	0.5-20.0	0.5	7.4	77
NEIPA	0.999	0.5-20.0	0.5	4.9	198
NDIPA	0.999	0.5-20.0	0.5	11.3	101
NDPA	0.999	0.5-20.0	0.5	8.5	86
NDBA	0.999	0.5-20.0	0.5	4.0	142
N-AFA	0.994	0.5-7.5	0.5	8.4	609

Abbr. = Abbreviation; CC = Calibration curve;  
Conc. = Concentration; S/N = Signal-to-noise ratio

The summary of content present in API and formulation samples as well as the recovery summary performed in API sample is summarized in Table 4 and 5, respectively.

Table 4: Summary of concentrations obtained in Afatinib API, and formulation samples are shown below.

Content in Afatinib sample (ppb)		
Abbr.	API	Formulation
NDMA	Below LOQ	Below LOQ
NMEA	Below LOQ	Below LOQ
NPYR	Below LOQ	Below LOQ
NDEA	Below LOQ	Below LOQ
NPIP	Below LOQ	Below LOQ
NEIPA	Below LOQ	Below LOQ
NDIPA	Below LOQ	Below LOQ
NDPA	Below LOQ	Below LOQ
NDBA	Below LOQ	Below LOQ
N-AFA	Below LOQ	Below LOQ

Table 5: Summary for samples spiked at 500 ppb for NDMA and 250 ppb for rest of the compounds.  
(Results expressed are relative to sample concentration)

% Recoveries of N-nitrosamines and Nitroso Afatinib in Afatinib API				
Abbr.	Amt. in sample (ppb)	Amt. obtained (ppb)	Amt. spiked (ppb)	% Rec.
NDMA	Below LOQ	433.7	500	87
NMEA	Below LOQ	252.8	250	101
NPYR	Below LOQ	304.4	250	122
NDEA	Below LOQ	292.1	250	117
NPIP	Below LOQ	252.8	250	101
NEIPA	Below LOQ	251.7	250	101
NDIPA	Below LOQ	250.0	250	100
NDPA	Below LOQ	294.1	250	118
NDBA	Below LOQ	253.3	250	101
N-AFA	Below LOQ	219.6	250	88

% Rec. = Percentage recovery; Amt. = Amount

Nexera, Labsolutions, DUIS, Shim-pack Scepter, IonFocus, and UF-Qarray are trademarks of Shimadzu Corporation or its affiliated companies in Japan and/or other countries.

## Conclusion:

1. Quantitation of 9 N-nitrosamines and NDSRI in Afatinib API and formulation was successfully demonstrated on Shimadzu LCMS-8060NX equipped with DUIS source.
2. Repeatability for N-nitrosamines and NDSRI was found to be less than 15.0 %.
3. Recoveries for all N-nitrosamines and NDSRI were found to be between 85-125 %.
4. The newly developed IonFocus™ ion source unit and patented lens system (UF-Qarray™ II) of LCMS-8060NX improves system robustness by efficiently introducing only ions into the mass spectrometer and removing unwanted neutral particles and contaminants.
5. Revolutionary DUIS ion source with ion focus technology not only detect compounds of diverse nature but also improves baseline by eliminating contaminants.



# SHIMADZU

Shimadzu Corporation

www.shimadzu.com/an/

Shimadzu Analytical (India) Pvt. Ltd.

www.shimadzu.in

**For Research Use Only. Not for use in diagnostic procedures.**

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. See <http://www.shimadzu.com/about/trademarks/index.html> for details.

Third party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "®".

Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.

06-SAIP-LC-076-EN

First Edition: Aug. 2025

➤ Please fill out the survey

## Related Products

Some products may be updated to newer models.



### ➤ Nexera series

Ultra High Performance Liquid Chromatograph



### ➤ LCMS-TQ RX Series Triple Quadrupole LC-MS/MS

Triple Quadrupole LC-MS/MS

## Related Solutions

➤ Pharmaceutical and  
Biopharmaceutical

➤ Small Molecule  
Pharmaceutical

➤ Price Inquiry

➤ Product Inquiry

➤ Technical Service /  
Support Inquiry

➤ Other Inquiry